IMTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IMTX is not a strong buy right now for a Beginner investor focused on long-term investing, even though analyst coverage is positive and pre-market price is holding near support. The stock has promising pipeline catalysts, but the technical setup is mixed, latest financials remain deeply negative, and there is no strong proprietary trading signal today. For an impatient investor who does not want to wait for a better entry, I would not call this a clear buy at the current price of 10.99.
The short-term chart is mixed. MACD histogram is slightly negative and expanding, which points to fading momentum. RSI at 42.39 is neutral to mildly weak, so the stock is neither oversold nor strongly trending up. On the positive side, the moving averages are bullish with SMA_5 > SMA_20 > SMA_200, which supports the broader trend. Price at 10.99 is just above the first support area around 10.91 and below the pivot at 11.233, so the stock is sitting near a decision zone rather than a confirmed breakout.
The stock also has a near-term technical support zone around 10.91 to 10.71 that may attract buyers.
There was no news in the recent week, so there is no fresh event-driven catalyst today. MACD is weakening, and the stock is trading below the pivot level. Financial results remain poor, with Q3 2025 revenue down 89.74% year over year and net income still sharply negative at -50.5 million. Hedge funds and insiders are neutral, and there is no recent congress or influential-person trading support.
Latest quarter reported: 2025/Q3. Revenue fell to 5.187 million, down 89.74% year over year, which is a significant decline in top-line growth. Net income was -50.545 million, still deeply negative, although the year-over-year comparison improved because losses narrowed in relative terms. EPS was -0.42, also still negative. Gross margin was 100%, but that does not offset the weak revenue base and continued operating losses. Overall, the latest quarter shows a company still in development-stage financial condition rather than a steadily improving commercial business.
Analyst tone is positive and getting stronger. TD Cowen initiated Buy coverage, Jefferies also started at Buy with an $18 target, and Mizuho lifted its target to $25 from $23 with an Outperform rating. The Wall Street pros are bullish on the pipeline and see anzu-cel and the melanoma readout as important de-risking catalysts. The pro side is meaningful upside potential if the pipeline delivers; the con side is that these targets rely on future clinical success, while current financials remain weak and there is no fresh catalyst in the last week.
